ORMP - Oramed Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
8.36
-0.06 (-0.71%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close8.42
Open8.41
Bid0.00 x 0
Ask0.00 x 0
Day's Range8.26 - 8.64
52 Week Range5.85 - 11.34
Volume33,347
Avg. Volume39,254
Market Cap119.599M
Beta0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.76
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Trade prices are not sourced from all markets
  • ACCESSWIRE16 hours ago

    Blog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular Atrophy

    Stock Monitor: Oramed Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 18, 2018 / Active-Investors.com has just released a free research report on AveXis, Inc. (NASDAQ: AVXS ). If you want ...

  • GuruFocus.com6 days ago

    Three Diabetes Clinical Trials to Watch in 2018

    Outcomes on these three clinical trials in diabetes this year could change the way the disease is treated going into the next decade.

  • Associated Press7 days ago

    Oramed reports 1Q loss

    The Jerusalem-based company said it had a loss of 18 cents per share. The drug maker posted revenue of $611,000 in the period. Oramed shares have decreased 2 percent since the beginning of the year. The ...

  • Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule
    PR Newswire2 months ago

    Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule

    "Data from our directed preclinical NASH studies and clinical studies of ORMD-0801 in diabetics has revealed, through exploratory endpoints, that our oral insulin capsule has the ability to reduce inflammation of the liver.  Incidence of NASH is rapidly increasing, similar to the rates of increase in diabetes.  We look forward to exploring ORMD-0801 as a potential treatment for NASH," stated Oramed CEO, Nadav Kidron.

  • Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins
    PR Newswire3 months ago

    Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins

    JERUSALEM, Oct. 31, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of intent to grant a patent for broader claims for its invention titled, 'Methods and Compositions for Oral Administration of Proteins'. The patent covers Oramed's drugs including its oral insulin capsule ORMD-0801 which is currently in clinical development for type 1 and type 2 diabetes, as well as ORMD-0901, an oral GLP-1 analog capsule. Oramed's invention is designed to prevent the breakdown of protein-based drugs in the gastrointestinal track and promotes its crossing the small intestine.

  • PR Newswire3 months ago

    Oramed to Present at the Diabetes Technology Meeting

    JERUSALEM , October 24, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed to Present at the Disruptive Growth Showcase Conference
    PR Newswire4 months ago

    Oramed to Present at the Disruptive Growth Showcase Conference

    JERUSALEM , Sept. 25, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, ...

  • GuruFocus.com4 months ago

    Oramed Now Has a Clear Path to Market With Oral Insulin

    A look at the most recent announcement about the company's efforts to bring oral insulin to market in the US

  • Zacks Small Cap Research4 months ago

    Oramed (ORMP): Successful Meeting with FDA for Oral Insulin

    By Grant Zeng, CFA NASDAQ:ORMP The FDA Meeting Earlier today (Sept. 5, 2017), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced that it has successfully concluded a meeting with the US FDA regarding ...

  • Oramed Announces Successful Meeting with FDA for Oral Insulin
    PR Newswire4 months ago

    Oramed Announces Successful Meeting with FDA for Oral Insulin

    JERUSALEM, Sept. 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the Company's novel oral insulin formulation. At the meeting, the FDA gave clear guidance that the regulatory pathway for submission of ORMD-0801, would be a Biologics License Application (BLA).  Such a pathway would grant a full 12 years of marketing exclusivity for ORMD-0801 if approved.  On top of this, an additional six months of exclusivity can be granted if the product also receives approval for use in pediatric patients. The FDA confirmed that the approach to nonclinical toxicology, CMC and qualification of excipients would be driven by their published guidance documents, consistent with the Company's expectations.  They also made specific recommendations for clinical trials designed to provide pivotal data prior to registration.

  • Oramed to Present at the Rodman & Renshaw Global Investment Conference
    PR Newswire5 months ago

    Oramed to Present at the Rodman & Renshaw Global Investment Conference

    JERUSALEM , August 29, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • GuruFocus.com5 months ago

    3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs

    Diabetes accounts for nearly 10% of US health care spending

  • Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
    PR Newswire6 months ago

    Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs

    JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs. "We are very pleased to welcome Dr. Bruce on board at this pivotal time for Oramed as we prepare for the initiation of a Phase III trial for our oral insulin capsule, ORMD-0801.  Dr. Bruce will be tasked with leading all of our clinical development programs, with the specific near-term focus on bringing our oral insulin (ORMD-0801) through regulatory approval and into commercialization," stated Oramed CEO, Nadav Kidron.

  • Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017
    PR Newswire6 months ago

    Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017

    JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock" at the upcoming BIT'S 5th World Congress of Diabetes-2017 and BIT's 6th World Congress of Endobolism-2017 in Prague, Czech Republic. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's PODTM technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
    PR Newswire6 months ago

    Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program

    JERUSALEM, July 11, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to schedule an End-of-Phase II meeting with Oramed for its successfully completed Phase IIb trial of its oral insulin capsule ORMD-0801 in the treatment of type 2 diabetes. The purpose of the End-of-Phase II meeting, which is expected to take place on August 31, 2017, is to review the Phase IIb results with the FDA and seek guidance from the regulatory agency on the clinical design and protocol of Oramed's upcoming pivotal Phase III trial, in preparation for filing a New Drug Application (NDA).

  • Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017
    Capital Cube6 months ago

    Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017

    Categories: Yahoo FinanceGet free summary analysis Oramed Pharmaceuticals, Inc. reports financial results for the quarter ended May 31, 2017. Highlights Summary numbers: Revenues of USD 0.62 million, Net Earnings of USD -1.97 million. Change in operating cash flow of -5.89% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • Associated Press6 months ago

    Oramed reports 3Q loss

    On a per-share basis, the Jerusalem-based company said it had a loss of 15 cents. The drug maker posted revenue of $617,000 in the period. Oramed shares have risen 36 percent since the beginning of the ...

  • Oramed Announces Dual-Listing on Tel Aviv Stock Exchange
    PR Newswire7 months ago

    Oramed Announces Dual-Listing on Tel Aviv Stock Exchange

    JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel Securities Authority to dual-list its common stock on the Tel Aviv Stock Exchange (TASE). Oramed common stock will commence trading on the TASE on July 12, 2017 under the ticker ORMP.  Based on the current market capitalization of the Company, it is expected that Oramed will be included in the TA SME-60 index.

  • Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule
    PR Newswire7 months ago

    Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule

    JERUSALEM, June 27, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, "Methods and Compositions for Treating Diabetes" The patent covers Oramed's invention of an oral insulin and glucagon-like peptide-1 (GLP-1) analog combination composition (or therapy). Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's POD™ technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed to Present at the American Diabetes Association 77th Scientific Sessions
    PR Newswire7 months ago

    Oramed to Present at the American Diabetes Association 77th Scientific Sessions

    JERUSALEM, June 6, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing the recent Phase IIb study of its orally ingestible insulin capsule, ORMD-0801, will be presented in a poster at the ADA 77th Scientific Sessions on June 9-13, 2017 in San Diego. The American Diabetes Association's Scientific Sessions offers researchers and health care professionals from around the world the unique opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care.

  • PR Newswire7 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK, June 5, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • Oramed to Present at Conferences Next Week
    PR Newswire8 months ago

    Oramed to Present at Conferences Next Week

    JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, ...

  • Oramed Granted Canadian Patent for GLP-1 Analog Capsule
    PR Newswire8 months ago

    Oramed Granted Canadian Patent for GLP-1 Analog Capsule

    JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, "Methods and Compositions for Oral Administration of Exenatide". Oramed's oral GLP-1 capsule based on the Company's Protein Oral Delivery (PODTM) technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.

  • Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017
    Capital Cube9 months ago

    Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Oramed Pharmaceuticals, Inc. reports financial results for the quarter ended February 28, 2017. We analyze the earnings along side the following peers of Oramed Pharmaceuticals, Inc. – Novo Nordisk A/S Sponsored ADR Class B, Ultragenyx Pharmaceutical, Inc. and Lexicon Pharmaceuticals, Inc. (NVO-US, RARE-US and LXRX-US) that have also reported for this ... Read more (Read more...)